In this thirteenth video, the fifth from the afternoon breakout survivorship sessions, GRACE presents Exercise for Lung Cancer Patients, with Jeffrey Eagan DPT.
In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.
In this eleventh video from the Targeted Therapies in Lung Cancer Patient Forum, the third from the afternoon breakout survivorship sessions, GRACE presents Chemo Brain, with Denise Damek, MD.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
No Result Found